AKBA Akebia TherapeuticsWatchlist
About Akebia Therapeutics Company
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Ed Arce maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and raises the price target from $3.75 to $5.
Akebia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/17/2023 376.19% HC Wainwright & Co. $3.75 → $5 Maintains Buy 09/27/2023 257.14% HC Wainwright & Co. → $